Cabaletta Bio's core business segment revolves around the development of Chimeric AutoAntibody Receptor (CAAR) T-cell therapies. This innovative approach aims to precisely target and eliminate B cells responsible for producing autoantibodies that drive autoimmune diseases. The company's research and development efforts are focused on engineering T cells to express CAARs, which selectively bind to specific autoantigens on the surface of pathogenic B cells. This targeted elimination strategy has the potential to provide long-lasting remissions for patients with B cell-mediated autoimmune disorders. The lead product candidate, DSG3-CAART, is currently in Phase 1 clinical trials for mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Future opportunities include expanding the CAAR-T platform to address a wider range of autoimmune conditions, such as myasthenia gravis and hemophilia A with Factor VIII alloantibodies. Cabaletta Bio's strategic partnerships and collaborations with academic institutions and industry partners further strengthen its position in the rapidly evolving field of cell therapy.